DPC-168

• Description :

  DPC-168 is an orally effective CCR3 antagonist (IC50 = 41 nM) . DPC-168 exhibits a significant ability to inhibit eosinophil chemotaxis and pulmonary inflammation. DPC-168 can be used for research on airway inflammation[1].

• UNSPSC :

  12352005

• Target :

  CCR

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Field of Research :

  Inflammation/Immunology

• Smiles :

  O=C(N[C@H]1[C@H](CN2C[C@H](CC3=CC=C(F)C=C3)CCC2)CCCC1)NC4=CC=CC(C(C)=O)=C4

• Molecular Formula :

  C28H36FN3O2

• Molecular Weight :

  465.60

• References & Citations :

  [1]D'Elios M M, et al. Interfering with chemokines and chemokine receptors as potential new therapeutic strategies[J]. Expert Opinion on Therapeutic Patents, 2008, 18 (3) : 309-325.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [275810-55-4]